Pds Biotechnology CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd report a 4.99% passive beneficial ownership stake in PDS Biotechnology Corp.
NASDAQ
SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Passive Stake in PDS Biotechnology Corp
Armistice Capital, LLC and Steven Boyd have jointly disclosed a passive beneficial ownership of 9.99% in PDS Biotechnology Corp's common stock as of March 31, 2025.